|
Orthologous residues
|
|
rictor (human): T1135‑p, rictor (mouse): T1135‑p, rictor (rat): T1120‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), MEF (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
p70S6K (human)
|
siRNA inhibition of enzyme, genetic knockout/knockin of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
PI-103
|
|
|
|
decrease
|
|
|
LY294002
|
|
|
|
decrease
|
|
|
rapamycin
|
|
|
|
decrease
|
|
|
amino acids
|
|
|
|
increase
|
|
|
rapamycin
|
amino acids
|
|
|
inhibit treatment-induced increase
|
|
|
insulin
|
|
|
|
increase
|
|
|
rapamycin
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
EGF
|
|
|
|
increase
|
|
|
serum
|
|
|
|
increase
|
|
|
calyculin A
|
|
|
|
increase
|
|
|
U0126
|
|
|
|
no change compared to control
|
|
|
|
|
mTOR (human)
|
|
increase
|
mTOR siRNA decreases
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
14-3-3 epsilon (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|